Sandoz moves to block Amgen’s attorneys from prosecuting patents in IP spat

Intellectual Property 2025-05-06 11:41 pm | Melbourne
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.
For information on rights and reprints, contact subscriptions@lawyerly.com.au